Jack Pluenneke

🫀Pharmacist @midamericaheart | via @SLpharmacy & @VUMChealth | @UMKCpharmacy alum | #PharmICU | #ChiefsKingdom

[Novi Yanti Sari @slumberbell]

Just published in JACC @JACCJournals!🫀

Acute HF care is evolving:
📍Rapid diagnosis
📍Early decongestion
📍Timely GDMT initiation
📍Structured follow-up
📍Focus on long-term outcomes, not just symptom relief

Grateful to have contributed to this international collaboration & learned so much from the exceptional experts involved in this work. Congratulations to @Jolie_Bruno_ and @AlexMebazaa for the leadership & to all co-authors on this important publication🫀

Read the full paper🔗: https://t.co/408QmNOznr

#HeartFailure #AcuteHeartFailure #JACC @jozinetm @BiykemB @GianluSava @pmyhre

[JAMA @JAMA_current]

Short-term discontinuation due to adverse events was lowest for #ARB monotherapy and ARB plus calcium channel blocker regimens, compared with placebo. Combination therapies generally showed greater tolerability than monotherapies.

https://t.co/SUyLd4XZJh

[Ashley Miller @icmteaching]

Haemodynamic equations are useful. But they also mislead.

Take:

CO = HR × SV
CO ≈ (MAP − RAP) / SVR

Both are mathematically true. But they can make the variables they contain look like the controllers of output.

Often they are not.

In the intact circulation, these equations describe the resolved state of the system. They do not, by themselves, tell you what is supplying energy, what is constraining flow, or what is actually limiting output.

That is one of the central themes of our review:

Energy, flow and pressure in the cardiovascular system: a narrative review of how the circulation works.

https://t.co/L19bsDCzr6

[Eric Topol @EricTopol]

Just published @NEJM
Marked and durable reduction of LDL cholesterol with one shot PCSK9 gene base editing @skathire https://t.co/3fU9EjatjH

[NEJM @NEJM]

Original Article: Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis (TETON-1 and TETON-2) https://t.co/zlcSdKxEum

#ATS2026 | @atscommunity

[Ahmed Bennis MD 🫀 @drbennisahmed]

Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

https://t.co/benMlM395p

[Ahmed Bennis MD 🫀 @drbennisahmed]

🚨 NEW DATA: DECISION trial blinded withdrawal substudy #HeartFailure26
Stopping low-dose digoxin in HFrEF/HFmrEF (LVEF≤50%) on contemporary GDMT → 7-fold ↑ in worsening HF events over just 6 weeks (RR 7.55 [2.72–20.95])
Biomarkers told the same story:
↑ Heart rate +3.7 bpm (p=0.003)
↓ SBP -3.7 mmHg (p=0.014)
↑ NT-proBNP 900→1023 ng/L (p=0.002)
↓ eGFR -2.2 mL/min/1.73m² (p=0.002)
Placebo arm: no significant change in any parameter
Bottom line: Think twice before stopping digoxin in long-term HF patients — even in the era of BB, ARNI, SGLT2i & MRA
#HFTwitter #HeartFailure #Digoxin #DECISION

[JAMA @JAMA_current]

Meta-analysis of digitalis glycosides in HFmrEF or HFrEF indicated reduced risk of worsening #HeartFailure events, with no difference in mortality, across multiple randomized trials.

#HeartFailure26 @escardio

https://t.co/XOAkn89Tv0

[Ahmed Bennis MD 🫀 @drbennisahmed]

⚠️ Low BP in HFrEF — should it stop us from using GDMT? Data says: probably not.
From COPERNICUS, PARADIGM-HF, RALES/EMPHASIS-HF & DAPA-HF:
✅ Carvedilol beneficial even at SBP 85–95 mmHg
✅ Sacubitril/Valsartan consistent across all BP strata
✅ MRA & SGLT2i similarly effective in low BP groups
Low SBP is a reason to be careful — not a reason to stop. 💡
#HeartFailure26 #HF2026 #HFrEF #GDMT #Cardiology

[Ahmed Bennis MD 🫀 @drbennisahmed]

🚨 SUBCUT HF II results at #HeartFailure26
Subcutaneous furosemide via wearable minipump to support early discharge in acute HF:
✅ 4 more days alive & out of hospital at 30 days
✅ Index LOS reduced by 5.5 days (5.6 vs 11.0 days)
✅ Benefit sustained to 60 days
✅ Higher GDMT use at 60 days in early discharge arm
✅ Patient-operated, well tolerated, low complication rate
A new patient-centred care pathway for worsening HF & congestion 🏥➡️🏠
Campbell et al. @BHFCentre @UofGlasgow

[Jack Pluenneke @JackPluenneke]

And now $8/mo. Across the whole spectrum of HF, no excuse!

[Ahmed Bennis MD 🫀 @drbennisahmed]

The DELIVER trial (dapagliflozin in HFpEF/HFmrEF) didn’t just work — it worked fast. ⚡
Time to first statistical significance:
• CV death or worsening HF: Day 13 (HR 0.45; 95% CI 0.20–0.98; P=.046)
• Worsening HF alone: Day 16 (HR 0.45; 95% CI 0.21–0.96; P=.04)
Final follow-up benefit held strong:
• Primary endpoint: HR 0.82 (P<.001)
• Worsening HF: HR 0.79 (P<.001)
Two weeks. That’s when dapagliflozin starts saving patients from worsening heart failure.
#DELIVER #Dapagliflozin #HeartFailure #HFpEF #Cardiology #SGLT2i

[Brett Sperry, MD @BrettSperryMD]

🚨 Major ISHLT Consensus Update on Graft Dysfunction after Heart Transplant (10-yr update)!

PGD is now EGD (Early Graft Dysfunction <24h, unknown cause) + sEGD (Subsequent Early Graft Dysfunction 24-72h).

New classification:
• LV/biventricular vs isolated RV
• Severe EGD-LV: immediate (fail to wean CPB) vs delayed presentation (key prognostic difference)
• Severity simplified to non-severe vs severe based on MCS need (goodbye inotrope score!)

This standardization is critical right now as DCD, OCS, TA-NRP, SherpaPak & HOPE rapidly expand the donor pool & change preservation risks. Better risk stratification, prevention & management ahead!

Full consensus: https://t.co/wbyz7XIHJl

[Gregg Fonarow MD @gcfmd]

In-🏨 SGLTi for HF across the EF spectrum

☠️ ⬇️ by 39% during first 60 days

RR 0.61, 95% CI 0.47-0.81, p=0.0005

ARR 2.4% fewer ☠️s (95% CI 3.3%-1.2%)

NNT to prevent a ☠️ in next 60 days: 42

💊 cost, 60 day supply $17 (dapagliflozin)

[Gregg Fonarow MD @gcfmd]

Now available!

Generic dapagliflozin 10 mg

30 day supply, direct cash price

$8.36

@ACCinTouch @HFSA @American_Heart @AAHFN @SJGreene_md @ATSandhu @boback @NMHheartdoc @docsabe @HeartDocSadiya

[Eric Topol @EricTopol]

First randomized trial to show Ozempic reduces alcohol consumption in people seeking treatment for alcohol use disorder. Placebo-controlled, double-blind. Participants with BMI &gt;30 kg/m2.
https://t.co/M9Pk2gzKHD @TheLancet

[Ahmed Bennis MD 🫀 @drbennisahmed]

💥 Should we start SGLT2i DURING hospitalization for acute heart failure?
🔍 New systematic review & meta-analysis: 8 RCTs | n = 4,096 patients
✅ In-hospital SGLT2i initiation significantly reduces:
• All-cause death → RR 0.61 (95% CI 0.47–0.81)
• Worsening HF events → RR 0.67 (95% CI 0.45–0.94)
• Cardiovascular death → RR 0.68 (95% CI 0.47–0.99)
🟡 No significant reduction in HF rehospitalization (RR 0.87)
⚠️ No increase in acute kidney injury or serious adverse events
💡 Key message: early in-hospital initiation of SGLT2i is safe and reduces mortality — don’t wait for discharge!
📄 Ahmed et al. Journal of Cardiac Failure, 2026
#Cardiology #HeartFailure #SGLT2i #AcuteHF #GDMT #CardioTwitter

[Jack Pluenneke @JackPluenneke]

Join @Zac0x, @BenWangPharmD, and I as we take a deep dive into alternative decongestion strategies in AHF. Conversation will focus on practical considerations and allow for audience discussion and engagement. Oh yeah, and it’s Free! @HFSA @accpcardprn

[HFSA @HFSA]

Managing congestion in acute heart failure is evolving. Are you using the latest pharmacologic strategies at the bedside?

Join HFSA’s upcoming webinar to explore real-world approaches to decongestion including emerging therapies and practical tools you can apply immediately.

🗓 May 13 | ⏰ 6–7 PM ET
🎟 Complimentary registration

🔗 Save your spot: https://t.co/L8X8wqTxNX

[Circ: Heart Failure @CircHF]

Sacubitril/valsartan lowers BP; ANP drives early effects, while bradykinin contributes modestly during chronic HF therapy @adina_turcu
@vumchealth https://t.co/MH1v34Yi15

[Nicholas Morris @namorrismd]

#ICECAP results from #AANAM . Can we all agree that SOC for post arrest comatose patients should be normothermia?

[TIMI Study Group @TIMIStudyGroup]

We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.